Triple-negative breast cancer targeted drug carrier and preparation and application thereof
A triple-negative breast cancer and drug technology, applied in the field of medicine, can solve the problems of side effects and no TNBC targeted therapy drugs, etc., and achieve excellent targeting ability, molecular weight and reaction process controllable, good hydrophobic drug carrying capacity Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0041] SCL1A5 Gene Expression in Example 1 Breast Cancer and Different Types
[0042] Through the Cancer Genome Atlas (TCGA) data portal, query and obtain the data of SLC1A5 gene and breast cancer. The survival period of breast cancer patients and the expression of SLC1A5 gene in different types of breast cancer were found by analyzing the data. First, the clinical data of breast cancer patients and the corresponding expression level of SLC1A5 transcriptome were analyzed, including 113 normal human breast tissue samples and 5 breast cancer subtypes. Among them, 449 cases were luminal A type, 181 cases were luminal B type, 69 cases were HER2 positive, 166 TNBC Basal-like samples and 33 TNBC Normal-like samples were based on PAM50 intrinsic breast cancer subtypes. In order to analyze the differences in gene expression of SLC1A5 in patients with various subtypes of breast cancer, the expression data of SLC1A5 corresponding to the patients, that is, fragments per kilobase million...
Embodiment 2
[0049] The synthesis of embodiment 2 Gln-PEG-b-PAE copolymer
[0050] Design and synthesis of PEG-b-PAE by Michael addition reaction, then coupling glutamine to NH2-PEG-b-PAE copolymer by DCC / DMAP to obtain pH-responsive drug delivery carrier gln-PEG-b-PAE The copolymer realizes its function of targeting TNBC, and the specific synthesis process is as follows.
[0051] (1) Synthesis of Fmoc-PEG-b-PAE
[0052] Take Fmoc-protected PEG 1000 (0.1mmol) was dissolved in 10mL of anhydrous dichloromethane, and 2 times the equivalent of triethylamine was added, and then the reaction bottle was placed in cold hydrazine at 0°C, and acryloyl chloride (0.5mmol, aladdin, Shanghai, China) and stirred in cold hydrazine for 2 h. Subsequently, the reaction bottle was taken out to return the solution to room temperature and stirred for 24 h. After the reaction was completed, it was washed with dilute hydrochloric acid and concentrated in vacuo to obtain Fmoc-protected polyethylene glycol meth...
Embodiment 3
[0060] The synthesis of embodiment 3 Gln-PEG-b-PAE copolymer
[0061] Design and synthesis of PEG-b-PAE by Michael addition reaction, then coupling glutamine to NH2-PEG-b-PAE copolymer by DCC / DMAP to obtain pH-responsive drug delivery carrier gln-PEG-b-PAE The copolymer realizes its function of targeting TNBC, and the specific synthesis process is as follows.
[0062] (1) Synthesis of Fmoc-PEG-b-PAE
[0063] Take Fmoc-protected PEG 5000 (0.2mmol) was dissolved in 20mL of anhydrous dichloromethane, and 2 times the equivalent of triethylamine was added, and then the reaction bottle was placed in cold hydrazine at 0°C, and acryloyl chloride (0.4mmol, aladdin, Shanghai, China) and stirred in cold hydrazine for 2 h. Subsequently, the reaction bottle was taken out to return the solution to room temperature and stirred for 24 h. After the reaction was completed, it was washed with dilute hydrochloric acid and concentrated in vacuo to obtain Fmoc-protected polyethylene glycol meth...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More